289 related articles for article (PubMed ID: 34735669)
21. Somatostatin receptor imaging with (111)In-pentetreotide in gastro-intestinal tract and lung neuroendocrine tumors-Impact on targeted treatment.
Gerasimou G; Moralidis E; Gotzamani-Psarrakou A
Hell J Nucl Med; 2010; 13(2):158-62. PubMed ID: 20808990
[TBL] [Abstract][Full Text] [Related]
22. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.
Kwekkeboom DJ; Krenning EP; Scheidhauer K; Lewington V; Lebtahi R; Grossman A; Vitek P; Sundin A; Plöckinger U; ;
Neuroendocrinology; 2009; 90(2):184-9. PubMed ID: 19713709
[No Abstract] [Full Text] [Related]
23. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview.
Warner RR; O'dorisio TM
Semin Nucl Med; 2002 Apr; 32(2):79-83. PubMed ID: 11965602
[TBL] [Abstract][Full Text] [Related]
24. Somatostatin receptor targeting for tumor imaging and therapy.
Grötzinger C; Wiedenmann B
Ann N Y Acad Sci; 2004 Apr; 1014():258-64. PubMed ID: 15153442
[TBL] [Abstract][Full Text] [Related]
25. 68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs.
Werner RA; Bluemel C; Allen-Auerbach MS; Higuchi T; Herrmann K
Ann Nucl Med; 2015 Jan; 29(1):1-7. PubMed ID: 25139472
[TBL] [Abstract][Full Text] [Related]
26. Clinical relevance of somatostatin receptor imaging.
Reubi JC
Eur J Endocrinol; 1994 Dec; 131(6):575-6. PubMed ID: 7804438
[No Abstract] [Full Text] [Related]
27. CCK receptors in human neuroendocrine tumors: clinical implications.
Reubi JC
Scand J Clin Lab Invest Suppl; 2001; 234():101-4. PubMed ID: 11713969
[TBL] [Abstract][Full Text] [Related]
28. Design, preparation and biological evaluation of a
Behnammanesh H; Jokar S; Erfani M; Geramifar P; Sabzevari O; Amini M; Mazidi SM; Hajiramezanali M; Beiki D
Bioorg Chem; 2020 Jan; 94():103381. PubMed ID: 31662215
[TBL] [Abstract][Full Text] [Related]
29. The SNM practice guideline for somatostatin receptor scintigraphy 2.0.
Balon HR; Brown TL; Goldsmith SJ; Silberstein EB; Krenning EP; Lang O; Dillehay G; Tarrance J; Johnson M; Stabin MG;
J Nucl Med Technol; 2011 Dec; 39(4):317-24. PubMed ID: 22068564
[No Abstract] [Full Text] [Related]
30. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.
Slooter GD; Mearadji A; Breeman WA; Marquet RL; de Jong M; Krenning EP; van Eijck CH
Br J Surg; 2001 Jan; 88(1):31-40. PubMed ID: 11136306
[TBL] [Abstract][Full Text] [Related]
31. [Somatostatin receptor scintigraphy].
Rasmussen K; Nielsen JT; Rehling M
Ugeskr Laeger; 2005 Dec; 167(49):4647-50. PubMed ID: 16336855
[TBL] [Abstract][Full Text] [Related]
32. Peptide receptor imaging and therapy.
Kwekkeboom D; Krenning EP; de Jong M
J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002
[TBL] [Abstract][Full Text] [Related]
33. Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.
Ito T; Jensen RT
Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):15-24. PubMed ID: 27875420
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of a
Radford L; Gallazzi F; Watkinson L; Carmack T; Berendzen A; Lewis MR; Jurisson SS; Papagiannopoulou D; Hennkens HM
Nucl Med Biol; 2017 Apr; 47():4-9. PubMed ID: 28043006
[TBL] [Abstract][Full Text] [Related]
35. The radionuclide molecular imaging and therapy of neuroendocrine tumors.
Li S; Beheshti M
Curr Cancer Drug Targets; 2005 Mar; 5(2):139-48. PubMed ID: 15810878
[TBL] [Abstract][Full Text] [Related]
36. [Somatostatin receptors. A new way to diagnosis and therapy of neuroendocrine tumors].
Wängberg B; Nilsson O; Wigander A; Johansson V; Forssell-Aronsson E; Andersson P; Fjälling M; Tisell LE; Ahlman H
Lakartidningen; 1997 Mar; 94(10):829-30, 835-8. PubMed ID: 9102509
[TBL] [Abstract][Full Text] [Related]
37. Masking effect of chronic pancreatitis in the interpretation of somatostatin receptor positron emission tomography in pancreatic neuroendocrine tumors.
Treglia G; Farchione A; Stefanelli A; Brizi MG; Larghi A; Inzani F; Rindi G; Rufini V
Pancreas; 2013 May; 42(4):726-8. PubMed ID: 23591437
[No Abstract] [Full Text] [Related]
38. Guideline for PET/CT imaging of neuroendocrine neoplasms with
Bozkurt MF; Virgolini I; Balogova S; Beheshti M; Rubello D; Decristoforo C; Ambrosini V; Kjaer A; Delgado-Bolton R; Kunikowska J; Oyen WJG; Chiti A; Giammarile F; Sundin A; Fanti S
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1588-1601. PubMed ID: 28547177
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
40. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature.
Johnbeck CB; Knigge U; Kjær A
Future Oncol; 2014 Nov; 10(14):2259-77. PubMed ID: 25471038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
